BIOGEN INC.: directors' dealings · United States · SEC (Form 4)

About BIOGEN INC.

Biogen Inc. (ticker: BIIB) is a U.S.-listed biotechnology company traded on the NASDAQ market in the United States, with headquarters in Cambridge, Massachusetts. Founded in 1978, Biogen is one of the oldest independent American biotech companies and has built its identity around neuroscience, immunology, and, more recently, rare diseases. For investors, the company is best understood as a specialty biopharma platform focused on complex, high-unmet-need conditions rather than broad mass-market therapeutics. Biogen’s legacy was established in multiple sclerosis, where it became a long-standing pioneer and still maintains a broad, commercially important portfolio. Over time, the company expanded beyond MS into central nervous system and neurodegenerative diseases, including Alzheimer’s disease, as well as other neuroscience and rare-disease areas. Its current strategy combines internal R&D with targeted business development to strengthen its product franchise, broaden its therapeutic reach, and sustain long-term growth. Key commercial and pipeline themes include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, and selected rare-disease and immunology programs. Biogen also continues to invest in next-generation therapies and delivery technologies designed to improve treatment convenience and patient access. From a competitive standpoint, Biogen operates in highly contested therapeutic categories where differentiation depends on clinical data, regulatory execution, physician adoption, and reimbursement dynamics. Its main advantages are deep scientific expertise in neurology, a long operating history in specialty commercialization, and an international footprint. According to company disclosures, its therapies are available in more than 80 countries, and the company maintains major U.S. research, manufacturing, and operational hubs, especially in Cambridge and North Carolina. That U.S. industrial base remains an important part of the company’s execution model. Recent strategic developments have centered on the Alzheimer’s franchise and portfolio reshaping. Biogen and its partner Eisai have continued to advance LEQEMBI, including new dosing and delivery options aimed at broadening the treatment experience for early Alzheimer’s disease. The company has also pushed forward new pipeline assets, including tau-targeting approaches, while strengthening its rare-disease and immunology profile. In March 2026, Biogen announced an agreement to acquire Apellis, a move intended to expand its growth portfolio, add commercial products, and accelerate entry into nephrology. For equity investors, these steps suggest a company trying to offset mature legacy franchises with a more diversified next phase of growth. Overall, Biogen remains a major specialty biotech name with meaningful scale, strong neuroscience heritage, and a market position anchored in the United States. Its NASDAQ listing, Cambridge headquarters, and strategic focus on difficult-to-treat diseases make it a closely watched healthcare stock for long-term investors.